A study of Neoadjuvant Hormone therapy in patient with Advanced Prostate Cancer Undergoing Radical Prostatectomy.

Study identifier:D8664C09827

ClinicalTrials.gov identifier:NCT03971110

EudraCT identifier:N/A

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A Multi-centre, Single-arm, Prospective Study to Assess Efficacy and Safety of Neoadjuvant Hormone Therapy using Zoladex (Goserelin) and Casodex (Bicalutamide) in Patients with Advanced Prostate Cancer Undergoing Radical Prostatectomy.

Medical condition

Advanced Prostate Cancer

Phase

Phase 4

Healthy volunteers

No

Study drug

Zoladex and Casodex

Sex

All

Actual Enrollment

9

Study type

Interventional

Age

n/a - n/a

Date

Study Start Date: 28 Jan 2021
Primary Completion Date: 09 Nov 2022
Study Completion Date: 09 Nov 2022

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria